>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
miR126对角膜新生血管的影响
作者:程帅帅  张红 
单位:哈尔滨医科大学附属第一医院 眼科医院, 黑龙江 哈尔滨 150000
关键词:角膜新生血管 血管内皮生长因子 微小RNA 微小RNA126 文献综述 
分类号:R77
出版年·卷·期(页码):2015·34·第五期(828-831)
摘要:

角膜新生血管是导致视力减退的主要原因之一,多种生长因子可能与其存在着密切的关系,微小RNA(miRNA)可能调控这些生长因子的表达。miRNA126(miR126)被证明与角膜新生血管关系密切,通过影响相应靶基因的表达调控血管新生。作者对此进行综述。

参考文献:

[1] CARMELIET P.Angiogenesis in health and disease[J].Nat Med,2003,9(6):1873-1878.
[2] ALEJANDRO A,DARLENE M,FLORENCE C,et al.The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis[J].Dev Cell Science,2008,15(2):261-271.
[3] HOOD J D,BEDNARSKI M,FRAUSTO R,et al.Tumor regression by targeted gene delivery to the neovasculature[J].Sci,2002,296(5577):2404-2407.
[4] HE L,HANNON G J.MicroRNAs:small RNAs with a big role in gene regulation[J].Nat Rev Genet,2004,5(7):522-531.
[5] HEUSSCHEN R,van GINK M,GRIFFIOEN A W,et al.MicroRNAs in the tumor endothelium:novel controls on the angioregulatory switchboard[J].Biochem Biophys Act,2010,1805(1):87-96.
[6] 沈永斌,李伟东,姜维良,等.微小RNA-126转染对内皮祖细胞体外生成血管能力的影响[J].临床荟萃,2013,28(10):1123-1126,封3.
[7] AGRAWAL S,CHAQOUR B.MicroRNA signature and function in retinal neovas-cularization[J].Biol chem,2014,5(1):1.
[8] MAMORU K,YUKIHIRO M,KAZUKO N,et al.miR-126 regulates angiogenic signaling and vascular integrity[J].Dev Cell,2008,15(2):272-284.
[9] TANIGUCHI K,KOHNO R,AYADA T,et al.Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling[J].Mol Cell Biol,2007,27:4541-4550.
[10] UEKI K,FRUMAN D A,YBALLE C M,et al.Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling[J].Biol Chem,2003,278:48453-48466.
[11] WANG S,OLSON E N.AngiomiRs-key regulators of angiogenesis[J].Curr Opin Genet Devel,2009,19(3):205-211.
[12] LING H,FABBRI M,CALIN G A.MicroRNAs and other noncoding RNAs as targets for anticancer drug development[J].Nat Rev Drug Discov,2013,12:84-865.
[13] SGUIN R M,FERRARI N.Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease[J].Expert Opin Investig Drugs,2009,18:1505-1510.
[14] THUM T.MicroRNA therapeutics in cardiovascular medicine[J].EMBO Mol Med,2012,4:3-14.
[15] 刘成刚,周善璧.miR-184在碱烧伤大鼠角膜新生血管中的表达及靶基因预测分析[J].基础医学与临床,2013,33(5):588-592.
[16] 迟源,王海林,谢晚晴,等.MicroRNA调节视网膜新生血管研究进展[J].眼科新进展,2013,33(2):193-196.
[17] REDIS R S,CALIN S,YANG Y,et al.Cell-tocell miRNA transfer:from body homeostasis to therapy[J].Pharmacol Ther,2012,136:169-171.
[18] CREEMERS E E,TIJSEN A J,PINTO Y M.Circulating microRNAs:novel biomarkers and extracellular communicators in cardiovascular disease[J].Circ Res,2012,110:483-495.
[19] CURSIEFEN C,COLIN J,DANA R,et al.Consensus statementon indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation:outcome of an expert roundtable[J].Br J Ophthalmol,2012,96:3-9.
[20] ZHU N,ZHANG D,XIE H,et al.Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2[J].Mol Cell Biochem,2011,351(1-2):157-164.
[21] AZAR D T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing(an American Ophthalmological Society thesis)[J].Trans Am Ophthalmol Soc, 2006,104:264-302.
[22] MADDULA S,DAVIS D K,MADDDULA S,et al.Horizons in Therapy for Corneal Angiogenesis[J].Ophthalmol,2011,118(3):591-599.
[23] QAZI Y,MADDULA S,AMBATI B K.Mediators of ocular angiogenesis[J].J Genet,2009,88(4):495-515.
[24] AIELLO L P,WONG J S.Role of vascular endothelial growth factor in diabetic vascular complications[J].Kidney Int Suppl,2000,58:S113-119.
[25] PATHOL A J,DVORAK H F,BROWN L F,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability,andangiogenesis[J].Ophthalmol,1995,146(5):1029-1039.
[26] SENGER D R,LEDBETTER S R,CLAFFEY K P,et al.Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin,osteopontin,and thrombin[J].Am J Pathol,1996,149(1):293-305.
[27] KLETTNER A,ROIDER J.Treating age-related macular degeneration-interaction of VEGF-antagonists with their target[J].Mini Rev Med Chem,2009,9:1127-1135.
[28] 鲍玉洲,张艳敏,李建新.人表皮生长因子真核细胞缓释型滴眼剂的基因治疗研究[J].河南医学研究,2007,16(1):79.
[29] CASEY R,LI W W.Factors controling ocular angiogenesis[J].Am J Ophthalmol,1997,124(4):521-529.
[30] BARKER K S, PARK H, PHAN Q T, et al. Transcriptome profile of the vascular endothelial cell response to Candida albicans[J].J Infect Dis,2008,198:193-202.
[31] RISAU W.Mechanisms of angiogenesis[J].Nat,1977,386:671-674.
[32] GIACOMINI C,FERRARI G,BIGNAMI F,et al.Alkali burn versus suture-induced corneal neovascularization in C57BL/6 mice:an overview of two common animal models of corneal neovascularization[J].Exp Eye Res,2014,121:1-4.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405524 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364